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ABSTRACT
Introduction: High-dose conditioning regimens for allogeneic hematopoietic cell transplantation (allo-
HCT) as well as intensive poly-chemotherapy for acute myeloid leukemia (AML) induce prolonged
periods of neutropenia. The duration of the neutropenia is particularly long following umbilical cord
blood transplantation (UCBT).
Areas covered: After briefly reviewing the impact of hematopoietic growth factors administration to
hasten hematologic reconstitution after allo-HCT or intensive AML chemotherapy, this article sum-
marizes recent approaches that have been investigated to prompt hematologic reconstruction after
UCBT or intensive AML chemotherapy.
Expert opinion: In the allo-HCT setting, administration of G-CSF or GM-CSF shortened the duration of
the neutropenia but failed to decrease infection-related mortality or to improve survival. Novel
approaches to hasten hematological reconstruction after UCBT such as double UCBT with expansion
of one of the 2 UCB units with Notch ligand, mesenchymal stromal cells, nicotinamide, or StemRegenin
1, co-transplanting a single UCB unit with HLA-haploidentical CD34+ cells, or increasing UCB HSC
homing to marrow niches via direct intra bone UCB administration, pulse treatment with dmPGE2 or
enforced fucosylation are promising and deserve further investigations in prospective phase III studies.
In the AML setting, G-CSF or GM-CSF administration after intensive chemotherapy decreased the
duration of the neutropenia without improving survival.
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The incidences of nonrelapse mortality following allogeneic
hematopoietic stem cell transplantation (allo-HCT) or inten-
sive chemotherapy for acute myeloid leukemia (AML) have
been substantially reduced in the last decades [1,2].
Nevertheless, high-dose conditioning regimen administered
before myeloablative allo-HCT as well as intensive che-
motherapy regimens used to treat AML still results in pro-
longed bone marrow aplasia and particularly prolonged
neutropenia that often leads to bacterial and/or fungal
infections [3–6]. This is particularly the case when umbilical
cord blood (UCB) is chosen as stem cell source for allo-HCT
[4], or when the intensity of the chemotherapy is increased
in the induction or consolidation chemotherapy course of
AML [7].
Several studies have assessed the efficacy of hematopoie-
tic growth factors to shorten the duration of neutropenia
after allo-HCT [8,9] or in the induction chemotherapy course
for AML [10]. In the setting of allo-HCT, a meta-analysis
including data from all randomized studies demonstrated
that administration of granulocyte colony-stimulating factor
(G-CSF) successfully reduced the duration of neutropenia
and reduced the incidence of infection but failed to
decrease infection-related mortality [9]. In AML administra-
tion of G-CSF or of granulocyte macrophage colony-stimu-
lating factor (GM-CSF) after chemotherapy hasten neutrophil
recovery and shorten hospitalization without improving sur-
vival [10,11]. More recently, several approaches have been
assessed to shorten the duration of the neutropenic phase
during allo-HCT, and particularly after UCB transplantation
(UCBT). These approaches include direct intra bone implan-
tation of UCB, combination of single UCBT with CD34+ cells
from a G-CSF-mobilized HLA-haploidentical donor, UCB
expansion with immobilized Delta-1, mesenchymal stromal
cells, nicotinamide or StemRegenin 1 (SR1), or stem cell
modification aimed at increasing stem cell homing such as
pulse treatment with the 16,16-dimethyl prostaglandin E2
(dmPGE2) or enforced fucosylation [12,13]. Further,
approaches aimed at preventing viral infections after UCBT
by transfer of virus-specific T cells have been developed
[14–16].
In this article, after briefly discussing the potential role
of hematopoietic growth factors, we review recent
approaches that are currently assessed for hasting hema-
tologic recovery after allo-HCT or after intensive che-
motherapy for AML [17].
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2. Strategies to hasten hematologic recovery after
allo-HCT
2.1. Factors affecting hematologic recovery after allo-
HCT
The kinetics of hematologic reconstitution after allo-HCT are
influenced by several factors such as the stem cell source, graft
composition, the underlying disease, the conditioning regi-
men and the type of GVHD prophylaxis [18–22].
Stem cell source is one of the main factors affecting
engraftment kinetics [18,23–25]. As example in one large
study assessing the impact of graft source on unrelated
donor allo-HCT in adults with acute leukemia, median times
to neutrophil (defined as achievement of an absolute neutro-
phil count of ≥500 cells/mm3 for 3 consecutive days) and
platelet (defined as achievement of ≥20,000 platelets/mm3
unsupported by transfusion for 7 days) recoveries were 14
(range, 5–28) and 19 (range, 7–112) days respectively after
peripheral blood stem cell transplantation (PBSCT), 19 (range
6–41) and 28 (range, 10–150) days respectively after bone
marrow transplantation, and 24 (range, 12–68) and 52
(range, 22–275) days, respectively after UCBT [18].
The impact of graft composition is particularly marked in
the UCBT setting where transplantation of units containing
total nucleated cells (TNC) ≥2.5 × 107 cells/kg of recipient
body weight or ≥1.7 × 105 CD34+ cells/kg of recipient body
weight have been associated faster neutrophil engraftment
and reduced incidence of engraftment failure for adults with
acute leukemia [19,26]. There is also a positive correlation
between the CD34+ cell dose and the speed of neutrophil
and platelet engraftments following myeloablative BMT and
PBSCT [20], and with donor T cell engraftment after nonmye-
loablative conditioning [27].
The type of the conditioning regimen also impact engraftment
kinetics after allo-HCT. Specifically, the use of total-body irradiation
based myeloablative conditioning has been associated with faster
neutrophil and platelet engraftment than chemotherapy only
based regimens after UCBT [18], while engraftment kinetics were
comparable in patients receiving UCBT after myeloablative or
reduced intensity conditioning (RIC) [28].
Finally, regarding GVHD prophylaxis, the use of antithymo-
cyte globulin (ATG) in the conditioning regimen as well as
postgrafting immunosuppression with methotrexate have
each been associated with a delayed hematologic recovery
[29–31].
2.2. Hematopoietic growth factors
Several registry and prospective randomized studies have
assessed the impact of G-CSF after allo-HCT. Specifically, two
registry studies, one from the European Society for Blood and
Marrow Transplantation (EBMT) and one from the Center for
International Blood and Marrow Transplant Research (CIBMTR)
demonstrated faster neutrophil engraftment in patients given
G-CSF [32,33]. This was confirmed in three prospective rando-
mized studies (Table 1). Specifically, Ernst et al. reported the
results of a randomized phase III placebo-controlled trial of
G-SCF administration after allogeneic bone marrow transplan-
tation (BMT; n = 51) [8]. G-CSF was administered from day 0 to
engraftment or day +42 at the dose of 5 µg/kg. Patients
randomized in the G-CSF group had significantly faster neu-
trophil engraftment than control patients (15 vs. 19 days,
p < .001), while other transplantation outcomes were similar
in the two groups of patients. Bishop et al. performed a
randomized double blind trial of G-CSF administration in
patients receiving PBSC from HLA-matched related donors
[34]. G-CSF was administered at the dose of 10 µg/kg from
day 0 to neutrophil recovery. The incidence of neutrophil
recovery was significantly faster in patients randomized in
the G-CSF arm (11 vs. 15 days, p = .008). Similarly, Przepiorka
et al. randomized 42 adult patients given PBSC from HLA-
identical sibling donors to receive or not G-CSF at 10 µg/kg
from day 1 to neutrophil recovery [35]. Again patients rando-
mized in the G-CSF arm had faster neutrophil recovery (12 vs.
15 days, p = .002) and a trend for earlier hospital discharge (16
vs. 20 days, p = .05). Taken together, these studies suggest
that administration of G-CSF after allo-HCT decreases the time
Article highlights
● G-CSF administration significantly prompts neutrophil recovery after
allo-HCT or intensive chemotherapy for AML.
● G-CSF administration after allo-HCT or intensive chemotherapy for
AML does not improve OS.
● Double UCBT allows patients without a sufficiently rich single UCB
unit to benefit from UCBT.
● double UCBT failed to improve engraftment and other transplanta-
tion outcomes in patients who had a single UCB unit containing ≥2.5
x 107 TNC/kg recipient.
● double UCBT with expansion of one of the 2 UCB units with Notch
ligand, mesenchymal stromal cells, nicotinamide, or StemRegenin 1
results in prompt neutrophil engraftment.
● co-transplanting a single UCB unit with HLA-haploidentical CD34+
cells fastens neutrophil engraftment in comparison to double UCBT.
● increasing UCB HSPC homing to marrow niches via direct intra bone
UCB administration, pulse treatment with dmPGE2 or enforced fuco-
sylation also fastens neutrophil engraftment.
This box summarizes key points contained in the article.
Table 1. Selected randomized studies of G-CSF or GM-CSF administration after allo-HCT.
Time to 500 neutrophils in
G-CSF/control pts
Incidence of grade





First author Dose (μg/kg) /first day of G-CSF Stem cell source Number of pts Median (range) p-value % p-value % p-value
Bishop [34] 10/0 PBSC 44 11 (9–20) /15 (10–22) 0.008 48/61 0.4 65/58 .6
Przepiorka [35] 10/1 PBSC 42 12 (8–18)/15 (8–23) 0.002 27/34 NS 60/54 NS
Ernst [8] 5/0 BM 51 15 (1–22) /19 (15–28) <0.001 12/20 NS 84/69 NS
PBSC: G-CSF mobilized peripheral blood stem cells; BM: bone marrow; NR: not reported; Pts: patients.
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to neutrophil engraftment by 4 days and might decrease the
length of hospitalization without undue toxicities. However,
G-CSF administration failed to decrease the incidence of infec-
tions or to improve survival after allo-HCT [9].
GM-CSF has also been assessed after allo-HCT and also
resulted in faster neutrophil engraftment than placebo [9].
Interestingly, a recent prospective randomized phase IV
study suggested that GM-CSF might be more efficient than
G-CSF to prevent invasive fungal disease (p = .07) and was
associated with lower day 100 mortality (p = .04)[36].
Unfortunately, GM-CSF is no longer available in Europe.
Another approach to benefit from hematopoietic growth
factors has consisted of ex vivo incubating the grafts in their
presence for a few days before transplantation. Specifically,
incubating 1/3 of bone marrow grafts with interleukin-3 (IL-3)
and GM-CSF for 4 days enhanced hematopoietic recovery
after allogeneic BMT (the remaining 2/3 of the grafts was
infused unmanipulated on day 0) [37,38]. Similarly, infusion
ex vivo expanded (10 days in the presence of stem cell factor
(SCF), G-CSF and pegylated megakaryocyte growth and
development factor (PEG-MGDF)) peripheral blood progeni-
tor cells led to prompt neutrophil recovery after autologous
HCT [39].
Finally, a randomized study, published in 2014, has demon-
strated that recombinant human erythropoietin (Neorecormon,
Roche, administered once weekly at the dose of 500 U/kg per
week) hastened erythroid recovery and decreased red blood
cell transfusion requirements when started 4 weeks after allo-
HCT [40], a time where levels of endogenous erythropoietin are
inappropriately low in regard to the degree of anemia [41].
2.3. Novel approaches to hasten hematologic recovery
after UCBT
Given that hematological recovery is particularly slow after
UCBT, efforts at prompting engraftment have been mostly
studied in the UCBT setting. As mentioned above, there are
some correlations between the number of CD34+ cells and
TNC infused and the kinetics of neutrophil engraftment after
UCBT [19,26]. Initial approaches aimed at expanding UCB with
various cytokine cocktails met with little successes [12,13].
Fortunately, novel strategies aimed at increasing the number
of hematopoietic stem and progenitor cells (HSPCs) trans-
planted for UCBT or at increasing their ability to home to
their bone marrow niches have been much more encouraging
and might lead in the future to a regrowth of adult UCBT in
Europe, a transplant approach currently challenged by the
development of T-cell repleted HLA-haploidentical stem cell
transplantation [42–44]. These strategies have consisted of
double UCBT with or without expansion of one of the 2 UCB
units, cotransplanting a single UCB unit with HLA-haploiden-
tical CD34+ cells (haplo-cord transplantation), or increasing
UCB HSC homing to marrow niches via direct intrabone UCB
administration, pulse treatment with dmPGE2 or enforced
fucosylation [13,45] (Table 2).
2.3.1. Double units UCBT
Transplantation of two cord blood units, pioneered by the
Minnesota group, has been a major breakthrough in the
field of UCBT [54–56]. This approach allowed increasing the
dose of TNC transplanted, and, as a result, overcame the cell-
dose barrier that limits the feasibility of UCBT in adults.
Interestingly, while the two units contributed to hematopoi-
esis the first months after transplantation, only one of the two
transplanted unit was responsible for hematopoiesis by day
100 and beyond in 70–95% of the cases [57,58], depending of
the conditioning regimen used.
Based on the feasibility of double UCBT in adult patients,
the Blood and Marrow Transplant Clinical Trials Network (BMT-
CTN) conducted a prospective randomized trial of single ver-
sus double UCBT in children and adolescents with hematolo-
gic cancers [59]. Two hundred and twenty-four patients were
Table 2. Outcomes of selected studies of UCBT with engineered UCB-derived HSPCs or with cotransplantation of CD34+ cells from HLA-haploidentical donors.
Study Patients (#) Type of engineering
CD34 fold expansion/
days of ex vivo
expansion
Days to neutrophil engraftment:




Double UCBT with HSPCs expansion of one of the two units
Delaney et al. [46,47] 10 Notch-mediated HSPCs expansion 164/16 16 (7–34)a,b/26 (16–48) (p = 0.002) Unmanipulated
de Lima et al. [48] 31 MSCs-mediated HSPCs expansion 30/14 15c (9–42) vs. 21 (6–45)d (p = 0.08)
or 24 (12–52)e (p < 0.001)
Unmanipulated
Horwitz et al. [49] 11 Nam-mediated HSPCs expansion 72/21 13 (7–26) vs. 25 (13–38) (p < 0.001) Manipulated
Wagner et al. [50] 17 SR1-mediated HSPCs expansion 330/NR 15 (6–30) /24 (ND)
p < 0.001
Manipulated
Double UCBT with UCB chemical modification to improve homing of one of the two units
Cutler et al. [51] 12 dmPGE2 modification of 1 UCB unit NA 18 (14–31) vs. 21 (NR) (p<.05) Manipulated





Single UCBT with cotransplantation of CD34± cells from a G-CSF mobilized HLA-haploidentical donor (haplo cord)
Van Besien [53] 97 Unmanipulated UCBT
Cotransplantation of CD34+ cells from
HLA-haploidentical G-CSF mobilized
donors
NA NR but significantly faster (HR = 1.4,
p = 0.007)f
UCB
aMedian of 11 days in an updated cohort of 17 patients.
bOne of 10 patients had primary graft rejection.
cOne patient died on day 30 without engraftment.
dControls from the MD Anderson Cancer Research Center.
eControls from the CIBMTR.
fThe control group consisted of 193 double UCBT recipients.
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included. Each patient had two UCB units (a first containing
>2.5 × 107 TNC/kg recipient and a second containing
>1.5 × 107 TNC/kg recipient) that were HLA-matched at ≥4/6
loci. Main observations were that double UCB failed to
improve 1-year overall survival (OS; the primary end point of
the study). Further, in comparison to single unit recipients,
double UCB recipients had higher incidences of each grade
III-IV acute (23% vs. 13%, p = .02) and extensive chronic (15%
vs. 9%, p = .05) GVHD (Table 3).
Another prospective randomized study of single versus
double UCB was performed by the French group in children
and young adults with acute leukemia or myelodysplastic
syndrome [60]. One hundred and fifty-one patients were ran-
domized (and 137 were transplanted). Double UCBT failed to
decrease the transplantation strategy failure (defined as the
first of the four following events: transplant-related mortality,
autologous recovery, second allogeneic transplantation, or
infusion of an autologous stem cell rescue for engraftment
failure). Secondary end points were also similar in the two
groups of patients (Table 3).
Three large registry studies have compared UCBT outcomes in
adult patientswith acute leukemia transplantedwith one (contain-
ing >2.5 × 107 TNC/kg) versus two UCB units [61]. The first study
was reported by the CIBMTR and theNational Cord Blood Program
New York Blood Center and includedmainly patients transplanted
after myeloablative conditioning regimen [61]. The authors
observed similar engraftment kinetics, relapse, nonrelapse mortal-
ity (NRM), leukemia-free survival (LFS) andOS in patients given one
(n=106) versus two (n=303)UCBunits (Table 3). Eurocord and the
acute leukemia working party of the EBMT performed two sepa-
rate analyses, one in patients givenUCBT aftermyeloablative and a
second in patients receiving UCBT following RIC conditioning. In
the study reporting data of patients receiving UCB after myeloa-
blative conditioning (n = 239), among patients transplanted with
one single UCB unit, those receiving a thiothepa, busulfan and
fludarabine (TBF) regimen had better LFS than those transplanted
with busulfan- or TBI-based regimens [62]. When the single UCBT
group was restricted to patients given TBF-based conditioning,
transplantation outcomes were comparable between patients
receiving single or double UCBT, with the exception for a higher
incidence of grade II–IV acute GVHD in double UCBT recipients.
Similarly, in the study reporting data from patients receiving grafts
after RIC, engraftment kinetics, relapse, NRM, LFS and OS were
similar in patients given one (n = 172) versus two (n = 362) UCB
units, while therewas a suggestion for higher incidence of grade II-
IV aGVHD in double UCB recipients (36 vs. 28%, p = .08) [63]
(Table 3).
Taken together these results demonstrate that although
double UCBT achieved the aim of allowing patients without
a sufficiently rich single UCB unit to benefit from UCBT, it
failed to improve engraftment and other transplantation out-
comes in patients who had a single UCB unit containing
≥2.5 × 107 TNC/kg recipient. This is probably due to the
development of graft-versus-graft reactions, as recently evi-
denced by Lamers et al. [64]
2.3.2. Double units UCBT with expansion of one of the two
units
In addition of allowing successful UCBT in patients who lack a
single unit containing >2.5 × 107 TNC/kg, the development of
double UCBT provided a great platform for assessing strate-
gies of HSPCs expansion. Indeed, it offered the possibility of
cotransplanting an unmanipulated UCB unit containing a suf-
ficient number of TNC to secure long-term engraftment with a
second fully expanded unit. Further, this experimental setting
allowed quantifying the proportion of hematopoiesis originat-
ing from the unmanipulated versus the expanded unit by
assessment of blood or bone marrow chimerism [65].
Potential limitations of all these ex vivo UCBT expansion
approaches are their cost, the need for a GMP production
facility, and the difficulty of expanding HSPCs without indu-
cing their differentiation.
Indeed, the proliferation, expansion and differentiation of
HSPCs can be stimulated by several growth factors and cyto-
kines that are expressed in HSC niches. Most potent cytokines
for HSPCs expansion include SCF, thrombopoietin (TPO), and
flt3 ligand (flt3l) [66]. On the other hand IL-3, IL-6, IL-11 and
G-CSF have a tendency to generate differentiated cells [66].
Nevertheless, there are strong synergistic effects for HSPCs
expansion between SCF and flt3l, and between IL-6 and both
SCF and flt3l [66].
2.3.2.1. Notch-mediated expansion. Notch proteins impact
cell-fate decisions in many developmental systems. Notch
receptors 1 (Notch-1) and 2 (Notch-2) are expressed by
Table 3. Impact of double versus single UCBT on outcomes.
Relapse Nonrelapse mortality Treatment failure (inverse of LFS)
Study group Number of pts given sUCB/dUCB HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Studies in children and adolescents
BMT-CTN [59] 113/111 1.2 0.1 1.2 0.4 1.5 .08
(NR) (NR) (1.0–2.3)
French [60] 74/77 0.7 0.3 2.0 0.3 1.0 .7
(NR) (NR) (NR)
Studies in adults
CIBMTR [61] 106/303 0.9 .78 0.9 .56 1.0 .8
(0.6–1.6) (0.7–1.3) (0.8–1.2)
EBMT-Eurocord MACa[62] 88/83 0.8 .62 1.1 .75 1.0 1
(0.4–1.9) (0.6–1.9) (0.6–1.5)
EBMT-Eurocord RIC [63] 172/362 0.9 0.5 0.8 0.3 0.8 .2
(0.6–1.3) (0.5–1.2) (0.7–1.1)
aSingle UCB recipient group restricted to patients given UCB after TBF-based conditioning. CIBMTR: Center for International Blood and Marrow Transplant Research;
EBMT: European group for Blood and Marrow Transplantation; BMT-CTN: the Blood and Marrow Transplant Clinical Trials Network; Pts: patients.
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human HSPCs, while Notch ligands Delta-1 and Jagged-1 are
expressed by human BM stromal cells, endothelial cells and
osteoblasts [67]. Preclinical studies by Delaney et al. demon-
strated that ex vivo expansion of UCB with low density (2.5 µg/
mL) of an engineered form of the Notch ligand Delta1 in
immobilized form and a cytokine cocktail combining SCF,
TPO, flt3l, IL-6, and IL-3 allowed a >100 fold increase in the
absolute number of HSPCs, including those capable of repo-
pulating NOD/SCID mice [46,68]. Based on these observations,
the authors assessed the feasibility and safety of coinfusing a
first unmanipulated UCB unit with a second UCB unit that was
CD34-selected and then expanded ex vivo for 16 days on low-
density immobilized Delta-1, as described above [46]. The
authors evidenced durable engraftment in nine of the 10
included patients, while the remaining patient experienced
primary graft rejection. Median time to neutrophil engraft-
ment was 16 days (range, 7–34 days) in study patients versus
26 days (range, 16–48 days) in historical ones (p = .002).
Unfortunately, OS from study and historical patients was not
compared in this report. Interestingly, while long-term
engraftment originated mostly from the nonexpanded unit,
the expanded graft contributed almost exclusively to initial
myeloid engraftment [47]. The relatively weak contribution of
the Notch-mediated expanded unit to long-term hematopoi-
esis might suggest a deficiency in true stem cell expansion
with this technique and that the improved engraftment
observed was due mainly to expansion of short-term repopu-
lating progenitor cells. However, another potential explana-
tion might be that the unmanipulated (T-cell-replete unit)
developed an immune response against the expanded graft
leading to its subsequent rejection [45,64].
2.3.2.2. MSC-mediated expansion. Mesenchymal stromal
cells (MSCs) are fibroblast-like multipotent cells that have the
ability to support hematopoiesis on one hand, and to regulate
immune reactions such as GVHD on the other hand [69–72]. In
a preclinical study, investigators from the M.D. Anderson
Cancer Center observed that coculture of unmanipulated
UCB with bone marrow-derived MSCs in a culture media
supplemented with SCF, flt3l, TPO and G-CSF resulted in a
CD34+ and CD133+ expansions of eight and 31 fold after
14 days [73].
Based on these observations, de Lima, Shpall et al. launched a
pilot trial of double UCBT with the largest unit transplanted
unmanipulated (on day 0) and the second unit transplanted
also on day 0 after a 14-day ex vivo expansion in coculture
with MSCs. Results of the first 31 patients included have been
reported in the New England Journal of Medicine [48]. Median
time to neutrophil engraftment was 15 days (range, 9–42 days) in
the MSC group, compared with 24 days (range, 12–52 days) in
matched controls from the CIBMTR (p < .001). Further, the
median time to platelet engraftment was 42 days (range,
15–62 days) in expanded UCB recipients versus 49 days (range,
18–264 days) in controls (p = .03). Interestingly, engraftment
beyond 1 year originated primarily from the unmanipulated
UCB unit in all patients while cells from the expanded unit
persisted in 13% of the patients at 6 months. The relatively low
contribution of the MSC-mediated expanded unit to long-term
hematopoiesis suggest a deficiency in true stem cell expansion
with this technique and that the improved engraftment
observed was due to expansion of mainly short-term repopulat-
ing progenitors cells. Unfortunately, the authors did not compare
OS between MSC and matched control patients.
2.3.2.3. Nicotinamide-mediated expansion. Nicotinamide
(NAM) is a potent sirtuin 1 (SIRT1) inhibitor that facilitates
HSPCs expansion and inhibits HSPCs differentiation in vitro
[74]. Further, NAM increased both HSPCs migration toward
stromal cell derived factor-1 (SDF1) in transwell migration
assay and HSPCs homing/engraftment in NOD/SCID mice.
These observations prompted Horwitz et al. to conduct a
phase I trial of double UCBT with one unit infused unmanipu-
lated and the second infused after ex vivo expansion with
NAM (this expanded UCB product was termed NiCord) for
21 days [49]. The T cell containing fraction of the expanded
unit was refrozen following thaw and injected with the
expanded HSPCs fraction in order to retain immunologic prop-
erties and favor long-term engraftment of the expanded unit
through graft-versus-graft interactions (Figure 1). Neutrophil
engraftment was achieved after a median of 13 days (range,
7–26 days) in NiCord recipients (n = 11), versus 25 days (range,
13–38 days) in historical control patients (n = 17, p < .001). In
contrast, median time to platelet engraftment was comparable
in NiCord (33 days [range, 26–49 days]) and control (37 days
[range, 20–66 days]) patients (p = .09). Interestingly, in con-
trast to what has been observed with Notch-ligand or MSC
UCB expansion, the NiCord expanded unit was responsible for
long-term hematopoiesis in seven (and predominant in six) of
nine assessable patients. Further, the NiCord expanded unit
also contributed to T-cell chimerism in six out of nine evalu-
able patients. These preliminary results indicate that NAM-
mediated HSPCs expansion preserved or even expanded a
proportion of true stem cells while reinfusion of the T cell
containing fraction of the manipulated unit prevented its
immune-mediated rejection by residual immune cells from
the patient or by immune cells from the unmanipulated unit.
Based on these promising results, a prospective trial of
transplantation of a single NiCord expanded UCB after mye-
loablative conditioning has been recently launched
(Clinicaltrials.gov NCT01816230).
2.3.2.4. SR1-mediated expansion. Boitano et al. performed
an unbiased screen of 100,000 compounds to identify poten-
tial molecules that promote HSPCs expansion. The authors
identified a purine derivative, the StemRegenin 1 (SR1), as a
potent inhibitor of HSPCs differentiation [75]. SR1 acts by
antagonizing the aryl hydrocarbon receptor (AhR) and allows
dramatic HSPCs expansion in serum-free culture media sup-
plemented with SCF, flt3l, TPO and IL-6. Notably, culture with
SR1 for 3 weeks let to an 11-fold TNC increase and a 73-fold
increase for CD34+ cells in comparison to control cultures
(without SR1) with a >1000-fold CD34+ cell increase in com-
parison to input cells.
These impressive results led to the development of a
phase I and II study [50]. CD34+ selected cells from one
UCB were expanded in the presence of SR1, SCF, flt3l, IL-6
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and TPO (the product was referred as ‘HSC835’) (Figure 2).
Twenty patients were recruited and 17 completed the pre-
scribed treatment plan. These 17 patients were transplanted
with HSC835 along with its CD34-depleted fraction (as done
in the NiCord study to prevent immune rejection of the
expanded unit) and an unmanipulated UCB unit. As
expected, HSC835 graft contained significantly more CD34
cells than unmanipulated units, with a median of 17.5 × 106
Figure 1. Scheme of the study investigating NAM-mediated hematopoietic stem and progenitor cells (HSPCs) expansion [49] (the figure is reproduced from Baron,
Ruggeri and Nagler, ref [12] with permission). One UCB unit was CD133-selected and expanded ex vivo with NMA (this expanded UCB product was termed NiCord)
for 21 days. The T cell containing fraction of the expanded unit was re-frozen following thaw and injected with the expanded HSPCs fraction (in order to retains
immunologic potency and favor long-term engraftment of the manipulated unit) and with the unmanipulated UCB unit after myeloablative conditioning. Neutrophil
engraftment was very prompt and was achieved after a median of 13 days (range, 7–26 days) in NiCord recipients (n = 11), versus 25 days (range, 13–38 days) in
historical control patients (n = 17, P < 0.001). Further, the NiCord expanded unit was responsible for long-term hematopoiesis in 7 (and predominant in 6) of 9
assessable patients.
Figure 2. Scheme of the study investigating (SR1)-mediated hematopoietic stem and progenitor cells (HSPCs) expansion [50](the figure is reproduced from Baron,
Ruggeri and Nagler, ref [12] with permission). CD34+ selected cells from the smallest UCB were expanded in the presence of SR1, SCF, flt3l, IL-6 and TPO (the
product was referred as ‘HSC835’). Preliminary results including data from 19 patients were presented at the 2014 annual meeting of the American Society of
Hematology [76]. Seventeen patients were transplanted with HSC835 along with its CD34-depleted fraction (that was re-frozen after the CD34-selection) and an
unmanipulated UCB unit. Expansion with SR1 was impressive with the SR1 expansion culture yielding a median of 1,440 x 106 CD34+ cells (range, 140–6,362 x 106
CD34+ cells) after a median CD34+ cell enrichment of 328 fold (range, 66–844 fold). Consequently, HSC835 patients received an impressive median of 12.3 x106
CD34+ cells/kg (range, 2.3–48.5 x106 CD34+ cells/kg). This led to a very prompt engraftment with neutrophil engraftment occurring after 11 days (range, 6–23 days)
in the 11 of 17 patients in whom the HSC835 unit predominated, versus 23 days (range, 14–30 days) for those in whom the unmanipulated unit predominated.
Long- term chimerism was derived exclusively from the unmanipulated or the HSC835 unit in 6 patients each, while 5 patients experienced dual chimerism (CD3
chimerism from the unmanipulated unit and myeloid chimerism from the HSC835 unit).
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CD34 (range, 1.4–48.3) per kilogram body weight for
HSC835 units versus 0.2 × 106 CD34+ cells/kg present in
unmanipulated UCB units. In contrast, HSC835 graft con-
tained significantly less CD3+ T cells because it was derived
from the smaller unit and because of recryopreservation
nonspecific losses. The high numbers of CD34+ cells infused
led to a prompt engraftment with 100% of HSC835 patients
achieving neutrophil recovery a median of 15 days (range,
6–30 days) after UCBT. Median time to platelet recovery was
49 days (range, 28–136 days). Interestingly, neutrophil
engraftment occurred after at a median of 11 days (range,
6–23 days) in the 11 of 17 patients in whom the HSC835
unit predominated, versus 23 days (range, 14–30 days) for
those in whom the unmanipulated unit predominated.
Long-term chimerism was derived predominantly from the
unmanipulated or the HSC835 unit in six patients each,
while five patients experienced dual chimerism (CD3 chi-
merism from the unmanipulated unit and myeloid chimer-
ism from the HSC835 unit). Importantly, the authors
demonstrated the presence of interferon-γ producing T
cells directed against the losing graft, suggesting that unit
predominance was due to graft-versus-graft immune
reactions.
Based on these data, the investigators launched a pilot trial
aimed at evaluating the safety and efficacy of transplanting
HSC835 as sole stem cell source [76]. Of note, the two first
patients included achieved neutrophil engraftment on days 12
and 8, respectively. The trial that is still ongoing at the uni-
versity of Minnesota plans to recruit a total of 10 patients
(Clinicaltrials.gov: NCT01930162).
2.3.3. Cotransplantation a single UCB unit with HLA-
haploidentical CD34+ cells
Another approach to prompt hematologic recovery after sin-
gle unit UCBT in adults has consisted of coinfusion mobilized
stem cells from an HLA-haploidentical donor (haplo-cord
transplantation)[77]. This approach has been pioneered by
Magro et al. in a phase I and II study including 27 consecutive
patients with high-risk malignancies. These patients received a
single UCBT coinfused with CD34- (or CD133) selected PBSC
[77]. Neutrophil engraftment occurred 10 days (range,
9–36 days) after transplantation and was initially of PBSC
origin in 23 out of 27 patients. In contrast, full UCB-derived
chimerism was achieved in 93% of the patients. Recently, van
Besien et al. compared transplantation outcomes of a group
97 adult patients who underwent haplo-cord transplantation
at the University of Chicago or at the Well Cornell Medical
College and a group of 193 patients from the CIBMTR data-
base given double UCBT [53]. Conditioning regimen consisted
of fludarabine, melphalan and ATG in the patients that were
transplanted with the haplo-cord graft vs. low-dose TBI, cyclo-
phosphamide and fludarabine (TCF) in double UCB recipients.
Neutrophil and platelet cumulative incidences of engraftment
were significantly faster in haplo-cord than in double UCBT
patients (p < .01). Further, haplo-cord patients had also a
lower incidence of grade II–IV acute (HR = .3, p < 0.001) and
chronic (HR = .1, p < 0.001) GVHD, a lower risk of relapse
(HR = 0.5, p = .001) but had comparable OS (HR = 1.0) than
double UCB recipients.
2.3.4. Promotion of UCBT HSC homing
Although the technologies discussed above of ex vivo HSPC
expansion are becoming more and more successful, they
remain costly and technically challenging. Thus, investigators
are also developing easier approach to address the low HSPC
content of one UCB unit: improving their homing to bone
marrow niches. Most promising approaches have consisted
of direct intra bone UCB injection, pulse treatment of UCB
with dmPGE2, and UCB enforced fucosylation [12,13].
2.3.4.1. Direct intra bone UCB injection. Direct intra bone
UCB injection has been investigated in order to prompt
engraftment. This technique has been pioneered by the
Genova group who demonstrated the feasibility of this
approach using a single cord blood unit injected intra bone
in 32 patients with acute leukemia [78]. A retrospective study
by the Eurocord group has compared outcomes of 87 patients
given intra bone UCBT to those of 149 double UCBT recipients
[79]. All patients received UCBT after a myeloablative condi-
tioning regimen. Median TNC infused were 2.5 × 107/kg for
intra bone UCBT and 3.9 × 107/kg for double UCBT (p < 0.001).
In comparison to double UCB recipients, intra bone UCB
patients had faster neutrophil engraftment (23 vs. 28 days,
p = .001) while a higher proportion of intra bone patients
achieved platelet engraftment at 6 months (74% vs. 64%,
p = .003). Interestingly, intra bone patients had also a lower
incidence of grade II–IV acute GVHD (p < .01). However,
importantly, OS was superimposable in the two groups (47%
vs. 45% at 2 years).
2.3.4.2. Pulse treatment of UCB with dmPGE2. 16, 16-
dimethyl prostaglandin E2 (dmPGE2) increases HSPC numbers
in vivo without affecting their self-renewal and differentiation
potential [80]. This is achieved through cAMP-mediated reg-
ulation of the Wnt signaling pathway that controls HSPC pro-
liferation and apoptosis, and through increased expression
cyclinD1 and surviving [80,81]. Further, dmPGE2 is able to
enhance HSPC homing to bone marrow niches through upre-
gulation of CXCR4 surface expression [81].
Based on these observations, Cutler et al. conducted a
phase I study that assessed the safety and therapeutic poten-
tial of ex vivo modulation of a single UCB unit using dmPGE2
before reduced-intensity, double UCBT [51]. Twelve patients
were treated according to an optimized ex vivo dmPGE2 mod-
ulation protocol. The largest UCB unit was incubated with
10 µM of dmPGE2 for 2-h at 37°C and then infused to the
patients. The second UCB unit was infused unmanipulated 4 h
later. Median time to neutrophil engraftment was 17.5 days
(range, 14–31 days), significantly faster than in historical
patients (p = .04). Further, 10 of 12 patients had early and
sustained engraftment of the dmPGE2-UCB unit that contrib-
uted 100% to hematopoiesis.
The demonstration that the dmPGE2 unit was predominant
in 10 of 12 patients is encouraging, although this might also
be partly attributed to the fact that the unit that was modu-
lated with dmPGE2 was the biggest one. Nevertheless, based
on these encouraging results, dmPGE2 modulation of UCB is
currently being studied in a randomized phase II study in the
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double UCBT setting (Clinicaltrials.gov #NCT01627314). The
study plans to include up to 60 patients. The primary end
point is neutrophil engraftment and chimerism.
2.3.4.3. Enforced UCB fucosylation. Preclinical studies by
Xia et al. demonstrated that alpha1-3 fucosylation of UCB
HSPCs improved their homing and engraftment in NOD/SCID
mice [82]. Based on these findings, Popat et al. conducted a
pilot trial aimed at assessing the feasibility, safety, and efficacy
of enforced UCB cell surface fucosylation of a single UCB unit
in double UCBT setting [52]. Twenty-two patients with
advanced hematological malignancies were included. The
smallest UCB unit, containing a median of 2.4 × 107 TNCs/kg
(range, 1.8–3.3 TNCs/kg), was treated ex vivo for 30 min with
the enzyme fucosyltransferase-VI and guanosine diphosphate
fucose, while the largest unit, containing a median of 3.1 × 107
TNCs/kg (range, 2.2–5.9 TNCs/kg), was infused unmanipulated.
One patient experienced secondary graft failure and one
patient died before engraftment. The median time to neutro-
phil engraftment in the 20 assessable patients was 17 days
(range, 12–34 days), compared with 26 days (range,
11–48 days) for a group of 31 historical controls (p = .002).
Similarly, platelet engraftment was also faster in study patients
than in historical controls (p = 0.05). Interestingly, at day 30,
hematopoiesis originated solely from the unmanipulated UCB
in 40% of patients, solely from the fucosylated UCB unit in
another 40%, and from both units in the remaining 20% of
patients. Unfortunately, the impact of UCB fucosylation on OS
was not reported.
3. Strategies to hasten hematologic recovery after
intensive chemotherapy for AML
3.1. Hematopoietic growth factors
The use of hematopoietic growth factors such as G-CSF or GM-
CSF has been extensively studied in AML patients. On the one
hand, hematopoietic growth factors have the ability to
enhance the killing of leukemic blasts by cytotoxic drugs in
vitro. Specifically, exposure of leukemic cells to cytarabine in
the context of growth factor stimulation increased the forma-
tion of cytarabine-triphosphate, increased DNA uptake of radi-
olabeled cytarabine in leukemic cells, and enhanced leukemic
cell cytotoxicity [83]. This prompted several group of investi-
gators to conduct prospective randomized trials of leukemic
blast priming by G-CSF or GM-CSF during intensive che-
motherapy. Several of these trials demonstrated that adminis-
tration of G-CSF or GM-CSF during induction-remission
chemotherapy increased the proportion of patients who
achieve a complete remission [11,84], while others failed to
find such an association [83].
On the other hand, given that infections have been the leading
cause of mortality, the first month after induction chemotherapy
for AML, adminsitration G-CSF and GM-CSF have also been
assessed after administration of intensive chemotherapy in an
effort at enhancing neutrophil recovery and preventing infections.
Data from19 randomized trials performedbetween1990 and2003
and including a total of 5256 patients have been systematically
reviewed in ameta-analysis [10].Main findings of themeta-analysis
were that the administration of hematopoietic growth factors
failed to decrease the incidence of febrile neutropenia, bactere-
mias or fungal infections and did not impact overall survival.
Several of these randomized trials reported shorthened duration
of neutropenia with administration of hematopoietic growth fac-
tors, as well as shorter hospitalization. As example, in one of the
largest trial conducted by the EORTC/GIMEMA, patients who
received G-CSF after chemotherapy had shorter time to neutrophil
recovery (median, 20 vs. 25 days, p < .01) and slightly lower
hospitalization duration (mean, 27.2 vs. 29.7 days, p < .01) [11].
However, there was no benefit of G-CSF administration in term of
infection incidence or overall mortality. Their use should thus be
restricted topatientswhoare expected tohaveaprolongedperiod
of neutropenia such as patients who received an intensified form
of chemotherapy, those who are neutropenic at diagnosis [6], as
well as to patients with life-threatening infections. Further, it
should be stressed that the use of G-CSF or of GM-CSF might
increase the risk of secondary leukemia [85].
3.2. Infusion of a non-HLA-matched ex vivo expanded
UCB
Based on the very encouraging observed in the UCBT setting,
Delaney et al. conducted a phase I trial investigating the adminis-
tration of non-HLA-matched ex vivo expanded UCB to accelerate
hematopoietic recovery after intensive AML chemotherapy [17].
Twenty-nine patients were included. UCB were ex vivo expanded
after CD34-selection in the presence of the Notch ligand Delta1 as
described above. There were no unexpected toxicities associated
with expanded UCB administration, and specifically no cases of
GVHD, although there was more episode of febrile neutropenia
than in studypatients than inhistorical ones perhaps translating an
‘engraftment syndrome’. However neutrophil recovery and infec-
tion incidence were similar in patients given expanded UCB and in
historical controls. The potential utility of transplanting ex vivo
expanded UCB to accelerate hematopoietic recovery (and more
importantly improve OS) after intensive AML chemotherapy
deserves further evaluation in prospective phase II/III trials.
4. Conclusions
In the allo-HCT setting or in the setting of intense chemotherapy
for AML, administration of G-CSF shortened the duration of the
neutropenic phase without improving OS. Several novel
approaches aimed at prompting neutrophil recovery after UCBT
such as double UCBT with expansion of one of the two UCB units,
cotransplanting a single UCB unit with HLA-haploidentical CD34+
cells, or increasing UCB HSPC homing to marrow niches are
encouraging but should be assessed in phase III studies.
5. Expert opinion
High-dose conditioning regimen administered before myeloa-
blative allo-HCT as well as intensive chemotherapy regimens
used to treat AML result in prolonged bone marrow aplasia
and particularly prolonged neutropenia that often leads to
bacterial and/or fungal infections [3–6]. This is particularly
the case in the UCBT setting [4], or when the intensity of the
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chemotherapy is increased in the induction or consolidation
chemotherapy course of AML.
In the allo-HCT setting, administration of G-CSF or GM-CSF
shortened the duration of the neutropenic phase by approxi-
mately 4 days, decreased the length of hospitalization but
failed to decrease infection incidence or to improve OS. They
should thus not be systematically administered in that setting
although their use appeared to be safe and that they are
relatively cheap.
Several novel approaches to hasten hematological
reconstruction after UCBT are promising. Data from phase
I and II studies demonstrated that double UCBT with
expansion of one of the two UCB units with Notch ligand,
MSCs, nicotinamide, or SR1 all shortened the duration of
the neutropenic phase and accelerated platelet recovery.
Although notch-mediated and MSC-mediated expansion
techniques provided mainly short-term hematopoiesis,
UCB expansion with nicotinamide or with SRI provided
both short-term and long-term hematopoimesis. Phase III
trials are needed to assess the impact of these new
approaches on nonrelapse mortality and OS. Indeed, up
to now none of these novel approaches have demon-
strated improving OS. Further, other phase III studies are
needed to compare neutrophil engraftment with these
novel approaches (that are complicated, costly and require
GMP infrastructure) to systematic G(M)-CSF administration.
Another (less costly) approach to provide short time
hematopoiesis and decrease the duration of the neutrope-
nia and thrombocytopenia has consisted of cotransplant-
ing UCB with CD34+ selected cells isolated from an
apheresis product obtained in a HLA-haploidentical donor
mobilized with G-CSF. Preliminary encouraging results with
this approach have been confirmed by several indepen-
dent groups of investigators although there was no
demonstration that this approach improved OS. Thus,
here again, randomized are needed to compare haplo-
cord transplantation to UCBT or haplo-identical transplan-
tation alone.
Prompt engraftment has also been achieved with recent
approaches aimed at improving UCB-derived HPSCs homing
to BM niches such as direct intrabone UCB administration,
PGE2-priming of UCB or forced UCB fucosylation.
Confirmation of long-term safety as well as determination of
the impact of these approaches on the incidence of primary
and secondary graft failure and on OS will require longer
follow-up and larger studies.
In the AML setting, G-CSF or GM-CSF administration after
intensive chemotherapy decreased the duration of the neu-
tropenia without increasing the incidence of relapse but
unfortunately also without improving survival. Their use
should thus be restricted to patients who are expected to
have a prolonged period of neutropenia such as patients
who received an intensified form of chemotherapy or of
those who are neutropenic at diagnosis [6], as well as to
patients with life-threatening infections. Finally, administration
of Notch ligand expanded UCB to hasten hematological recon-
stitution in AML patients receiving intensive chemotherapy is
a novel interesting approach that deserve further assessment
in phases II/III trials.
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